Senolytic drug combo cleared 'zombie' cells and improved liver scarring in a first randomized trial

A drug pair best known for treating leukemia just delivered the strongest human evidence yet that clearing aged, non-dividing "zombie" cells can heal a scarred liver. In a phase-2, double-blind, randomized, placebo-controlled trial at Amsterdam University Medical Center, published in Nature Metabolism (October 2026), three intermittent cycles of dasatinib plus quercetin - senolytic drugs that selectively destroy senescent cells - produced at least a one-stage improvement in liver fibrosis in 47% of patients with fibrotic MASH, compared with 7% on placebo. It is the first controlled study to show that pharmacological clearance of senescent cells can change the histological severity of human fatty liver disease.

What did the trial actually do?

The trial enrolled 31 participants with biopsy-proven fibrotic MASH - the aggressive inflammatory form of fatty liver disease that can progress to cirrhosis and liver cancer. MASH stands for metabolic dysfunction-associated steatohepatitis: fat builds up in the liver, the tissue becomes inflamed, and scar tissue (fibrosis) replaces working liver cells. Participants were randomized one-to-one to receive either dasatinib 100 milligrams per day plus quercetin 1,000 milligrams per day, or matching placebo. The schedule was deliberately intermittent: three consecutive days per week for three weeks, then a four-week drug-free rest, with the seven-week cycle repeated three times over 21 weeks. The logic is that senescent cells take weeks to redevelop and do not divide, so brief pulses should clear them while limiting total drug exposure.

Where do mitochondria fit in?

The mitochondrial connection runs through senescence itself. Senescent cells are cells that have permanently stopped dividing - usually after DNA damage or oxidative stress - and instead of dying quietly, they linger and pump out a cocktail of proinflammatory and profibrotic signaling molecules called the senescence-associated secretory phenotype, or SASP. In the liver, that chronic inflammatory noise drives the inflammation and scar-tissue formation that define MASH. The same inflammatory cascade is closely tied to mitochondrial decline in aging tissue: stressed, inefficient mitochondria generate the oxidative damage that pushes cells into senescence, and senescent cells in turn poison their neighbors' mitochondria. What elevated this trial beyond a simple before-and-after biopsy result was the molecular layer: the team performed single-nucleus RNA sequencing on 53 frozen liver biopsy samples and found that two curated senescence gene signatures - SenMayo and a senescent hepatocyte signature - were significantly depleted in treated participants but not in the placebo group. The treatment also reduced the abundance of hepatic stellate cells, the liver's fibrogenic workhorse cells, and downregulated fibrosis genes including collagens and TGFB1.

Why does this matter for a disease this common?

The context makes the result notable. An estimated 40% of the global population has metabolic dysfunction-associated steatotic liver disease, and fibrosis stage is the single strongest predictor of liver-related complications and death - yet current approved therapies for MASH act mainly on metabolic drivers, not on the scarring machinery itself. A therapy that strikes at the fibrogenic machinery - depleting stellate cells and inflammatory cell populations, rather than merely resolving fat as a secondary effect - would be a genuinely new tool. Earlier phase-1 studies of the same drug pair in idiopathic pulmonary fibrosis and diabetic kidney disease had suggested senescent cells could be cleared in people, but no one had shown the approach could change liver tissue itself. The MASH resolution rate - improvement in the hepatocyte ballooning that defines the disease - was 53% in treated patients versus 7% on placebo.

The limits - and a serious safety warning

Three cautions matter enormously. First, the trial was small: 31 people, with only a handful of responder events, producing a wide confidence interval around the relative risk (6.59, with a 95% confidence interval from 0.93 to 46.53). The authors themselves describe the finding as hypothesis-generating rather than confirmatory, pending replication in a larger trial. Second, side effects were notably more frequent in the treatment arm - 82% of treated participants versus 43% on placebo, with headache the most common complaint - though nearly all events were mild to moderate and there were no cases of myelosuppression or QTc prolongation, the bone-marrow and cardiac toxicities most feared with dasatinib. Third and most important: dasatinib is a chemotherapy drug. It is approved for leukemia, it carries serious known toxicities, and this trial used it under close medical supervision in a hospital research setting. No one should attempt anything like this regimen outside of a clinical trial. The 21-week follow-up is also short for a fibrosis endpoint. If larger trials confirm the effect and nail down dosing, patient selection, and long-term safety, senolytics could move from an aging-biology curiosity to a real treatment category - but that confirmation has not happened yet.

Where the evidence stands

• Established: Dasatinib is an approved leukemia chemotherapy drug; cellular senescence and its inflammatory SASP secretions are established drivers of aging-related tissue decline, and liver fibrosis stage is the strongest predictor of mortality in MASH.
• Preliminary: The fibrosis improvement, MASH resolution, and senescence-signature depletion come from a single proof-of-principle trial of 31 patients over 21 weeks; the authors call the finding hypothesis-generating pending replication.
• Absent: Long-term safety data, replication in a larger trial, and any basis for use outside a clinical trial - dasatinib carries serious known toxicities.